Immunovant, Inc.
IMVT
Classement en actions
#3060
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Prix de l'action
$28.32
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$5.85B
Changement (1 jour)
-0.94%
Changement (1 an)
49.85%
Pays
US
Échange Immunovant, Inc. (IMVT)
Catégorie
Healthcare
Historique du prix de l'action pour Immunovant, Inc. (IMVT)
Prix de clôture le plus élevé : $30.02 le 2026-10-01
Prix de clôture le plus bas : $9.88 le 2019-06-01
Prix de clôture le plus bas : $9.88 le 2019-06-01
Historique du prix de l'action de Immunovant, Inc. de 2019 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 20.78% |
| 2025 | -7.38% |
| 2024 | -34.45% |
| 2023 | 163.89% |
| 2022 | 99.44% |
| 2021 | -84.02% |
| 2020 | 273.47% |
| 2019 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
